[go: up one dir, main page]

SG11202111441QA - Bispecific antibodies against pd-1 and lag-3 - Google Patents

Bispecific antibodies against pd-1 and lag-3

Info

Publication number
SG11202111441QA
SG11202111441QA SG11202111441QA SG11202111441QA SG11202111441QA SG 11202111441Q A SG11202111441Q A SG 11202111441QA SG 11202111441Q A SG11202111441Q A SG 11202111441QA SG 11202111441Q A SG11202111441Q A SG 11202111441QA SG 11202111441Q A SG11202111441Q A SG 11202111441QA
Authority
SG
Singapore
Prior art keywords
lag
antibodies against
bispecific antibodies
bispecific
antibodies
Prior art date
Application number
SG11202111441QA
Inventor
Qiong Wu
Yong Zheng
Yunying Chen
Jing Li
Original Assignee
Wuxi Biologics Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Biologics Ireland Ltd filed Critical Wuxi Biologics Ireland Ltd
Publication of SG11202111441QA publication Critical patent/SG11202111441QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
SG11202111441QA 2019-04-26 2020-04-24 Bispecific antibodies against pd-1 and lag-3 SG11202111441QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019084471 2019-04-26
PCT/CN2020/086830 WO2020216348A1 (en) 2019-04-26 2020-04-24 Bispecific antibodies against pd-1 and lag-3

Publications (1)

Publication Number Publication Date
SG11202111441QA true SG11202111441QA (en) 2021-11-29

Family

ID=72940870

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111441QA SG11202111441QA (en) 2019-04-26 2020-04-24 Bispecific antibodies against pd-1 and lag-3

Country Status (7)

Country Link
US (1) US20220213192A1 (en)
EP (1) EP3958900A4 (en)
JP (1) JP2022530496A (en)
KR (1) KR20220003567A (en)
CN (1) CN113727731B (en)
SG (1) SG11202111441QA (en)
WO (1) WO2020216348A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019179365A1 (en) * 2018-03-20 2019-09-26 WuXi Biologics Ireland Limited Novel anti-lag-3 antibody polypeptide
WO2024072893A1 (en) * 2022-09-28 2024-04-04 Incyte Corporation Anti-pd-1/lag-3 bispecific antibodies and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103396481B (en) * 2013-07-18 2015-06-03 华南理工大学 Heavy chain single-domain antibody of type-II dengue fever virus NS1 protein as well as preparation method and application of heavy chain single-domain antibody
CN103665165B (en) * 2013-08-28 2016-02-24 江苏匡亚生物医药科技有限公司 Bi-specific antibody of a kind of targeted human CD47-SIRP signal α path and its production and use
LT3116909T (en) * 2014-03-14 2020-02-10 Novartis Ag ANTI-BODY MOLECULES AGAINST LAG-3 AND THEIR USE
TWI693232B (en) * 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
WO2016089610A1 (en) * 2014-12-06 2016-06-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
MA40662B1 (en) * 2014-12-23 2020-12-31 Bristol Myers Squibb Co Antibodies against tigit
TWI773646B (en) * 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 Lag-3-binding molecules and methods of use thereof
WO2017019896A1 (en) * 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
UA121914C2 (en) * 2015-11-18 2020-08-10 Мерк Шарп І Доум Корп. Pd1 and/or lag3 binders
JP2019517539A (en) * 2016-06-07 2019-06-24 マクロジェニクス，インコーポレーテッド Combination therapy
MX2018015584A (en) * 2016-06-13 2019-09-18 I Mab Anti-pd-l1 antibodies and uses thereof.
DK3515938T3 (en) * 2016-09-21 2025-04-07 Cstone Pharmaceuticals MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1)
CN106279410B (en) * 2016-09-29 2019-08-20 华南理工大学 Two type dengue fever virus NS1 albumen multivalence nano antibodies of one kind and preparation method
UY37463A (en) * 2016-11-02 2018-05-31 Glaxosmithkline Ip No 2 Ltd UNION PROTEINS
CN110167966B (en) * 2017-01-06 2024-08-30 克雷森多生物制剂有限公司 Single domain antibodies against programmed cell death (PD-1)
EP3606955B1 (en) * 2017-04-05 2024-11-06 F. Hoffmann-La Roche AG Bispecific antibodies specifically binding to pd1 and lag3
CN108948194B (en) * 2017-05-19 2023-02-17 上海药明生物技术有限公司 Novel CTLA-4 monoclonal antibody
US20200079850A1 (en) * 2017-05-24 2020-03-12 Sutro Biopharma, Inc. Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
AU2018297061B2 (en) * 2017-07-06 2021-05-06 Merus N.V. Antibodies that modulate a biological activity expressed by a cell
WO2019062755A1 (en) * 2017-09-29 2019-04-04 Wuxi Biologics (Shanghai) Co., Ltd. Bispecific antibodies against EGFR and PD-1

Also Published As

Publication number Publication date
CN113727731A (en) 2021-11-30
JP2022530496A (en) 2022-06-29
EP3958900A1 (en) 2022-03-02
US20220213192A1 (en) 2022-07-07
EP3958900A4 (en) 2023-01-25
WO2020216348A1 (en) 2020-10-29
CN113727731B (en) 2023-06-02
KR20220003567A (en) 2022-01-10

Similar Documents

Publication Publication Date Title
HUS2500032I1 (en) Bispecific anti-bcma x anti-cd3 antibodies and uses thereof
IL279354A (en) Bispecific anti-psma x anti-cd28 antibodies and uses thereof
IL283493A (en) Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof
IL275740A (en) Single-domain antibodies and variants thereof against pd-1
IL276340A (en) Pd-1 agonist antibodies and uses thereof
IL283530A (en) Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
IL278844A (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
IL283945A (en) Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof
IL274438A (en) Single-domain antibodies and variants thereof against pd-l1
EP4008730A4 (en) Anti-ctla4-anti-pd-1 bispecific antibody and uses thereof
IL276260A (en) Single-domain antibodies against lag-3 and uses thereof
EP3688034A4 (en) Bispecific antibodies against EGFR and PD-1
IL275577A (en) Antibodies and variants thereof against pd-l1
IL277969A (en) Antibodies binding pd-1 and uses thereof
SG11202103221QA (en) Anti pd-l1 antibody and use thereof
EP4004054A4 (en) Anti-her2/anti-4-1bb bispecific antibody and use thereof
IL288692A (en) Bispecific antibody against α-syn/igf1r and use thereof
IL286918A (en) Bispecific antibody
SG11202111441QA (en) Bispecific antibodies against pd-1 and lag-3
EP4048700A4 (en) Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
HK40070104A (en) Bispecific antibodies against pd-1 and lag-3
EP4047021A4 (en) Ox40/pd-l1 bispecific antibody
HK40049066A (en) Bispecific anti-psma x anti-cd28 antibodies and uses thereof
HK40062198A (en) Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof
IL287093A (en) Combinations of anti-ildr2 antibodies and pd-1 antagonists